D Eshima

Radiation dosimetry for technetium-99m-MAG3, technetium-99m-DTPA, and iodine-131-OIH based on human biodistribution studies.

D. Eshima, A. Taylor, M. Stabin, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations.

D. Eshima, D Eshima, T Fauconnier, 2000, Seminars in nuclear medicine.

Measuring technetium-99m-MAG3 clearance with an improved camera-based method.

Ernest V. Garcia, D. Eshima, R. Folks, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers.

D. Eshima, A. Taylor, J. Vansant, 1997, Seminars in nuclear medicine.

Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement.

D. Eshima, D. Johnson, D L Johnson, 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Technetium-99m MAG3 kit formulation: preliminary results in normal volunteers and patients with renal failure.

P E Christian, P. Christian, D. Eshima, 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Evaluation of the hepatobiliary excretion of technetium-99m-MAG3 and reconstitution factors affecting radiochemical purity.

A T Taylor, D Eshima, T L Anderson, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe.

D. Eshima, A. Taylor, J. Vansant, 1996, Radiology.